Our history

Five years of strong progress

2019 / 20

Earnings per share
H1 2019 / 2020 – 4.66p
(Dec 2018 3.18p)
Net assets per share
46.6p
(June 2019 41.4p)
Pre-tax profit
£2,088,000
(Dec 2018 1,247,000)
Revenue
Fair value of the portfolio
£17,141,000
(June 2019 £13,689,000)

2019

Earnings per share
5.77p
Net assets per share
41.4p
Pre-tax profit
£2,350,000
Revenue
Fair value of the portfolio
£13,252,000
  • Portfolio companies announce 10 new industry collaboration agreements. Four new companies join Frontier IP portfolio.
  • Exscientia raises $26 million Series B funding, signs collaboration agreements with Roche, Celgene and GT Apeiron, meets first milestones for GSK and Sanofi.

2018

Earnings per share
2.36p
Net assets per share
33.2p
Pre-tax profit
£902,000
Revenue
Fair value of the portfolio
9,041,000
  • Molendotech signs collaboration agreement with Palintest, part of FTSE 100 group Halma plc; raises £500,000; Palintest launches water-testing kit based on its IP
  • Frontier IP increases stake in Fieldwork in return for providing direct, hands-on support for technical development

2017

Earnings per share
3.73p
Net assets per share
30.7p
Pre-tax profit
£1,229,000
Revenue
Fair value of the portfolio
6,729,000
  • Exscientia signs major collaboration agreements with Sanofi and GSK; receives €15 million investment from Evotec
  • Molendotech and The Vaccine Group spun out from the University of Plymouth to commercialise their water testing and vaccines to tackle zoonotic diseases technologies respectively

2016

Earnings per share
4.08p
Net assets per share
24.9p
Pre-tax profit
£1,131,000
Revenue
Fair value of the portfolio
4,651,000
  • Exscientia signs collaboration agreement with Evotec AG
  • Innovate UK awards Nandi £1m grant
  • Agreement signed with NOVA University Lisbon, NOVA School of Science and Technology (FCT Nova)
  • Tarsis Technology spun out of the University of Cambridge
  • Fieldwork Robotics incorporated to develop agricultural robots

2015

Earnings per share
2.76p
Net assets per share
20.9p
Pre-tax profit
£647,000
Revenue
Fair value of the portfolio
2,812,000
  • Alusid raises £266,000 to fund design of its first product
  • Pulsiv Solar raises £500,000 to accelerate product development

2014

Earnings per share
0.13p
Net assets per share
18.1p
Pre-tax profit
£27,000
Revenue
Fair value of the portfolio
£1,291,000
  • Nandi Proteins raises £660,000 to support development of its technology to replace E-number additives, fat and gluten in food
  • Exscientia signs collaboration agreement with Sunovion Pharmaceuticals
  • Cambridge Simulation Solutions spun out from the University of Cambridge